Related Experiment Videos
TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis
R N Maini1, M Elliott, F M Brennan
1Kennedy Institute of Rheumatology, London, UK.
Summary
Rheumatoid arthritis (RA) treatment is exploring immune responses. Blocking tumor necrosis factor alpha (TNF alpha) shows promise in controlling RA inflammation, offering a new therapeutic approach for immuno-inflammatory disorders.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- The precise immune mechanisms driving rheumatoid arthritis (RA) remain debated, despite a prevailing T-cell-driven disease hypothesis.
- A lack of identified specific antigens hindering RA research and therapeutic development.
- Previous trials targeting T-cell surface molecules (CD4, CD5, CD7) yielded inconclusive efficacy, suggesting limitations in broad T-cell depletion strategies.
Purpose of the Study:
- To explore alternative therapeutic strategies for rheumatoid arthritis beyond T-cell targeting.
- To evaluate the efficacy of targeting proinflammatory cytokines, such as TNF alpha, in managing RA.
- To assess the potential of anti-cytokine therapies in treating immuno-inflammatory disorders.
Main Methods:
- Review of clinical trial data for monoclonal antibodies targeting T-cell surface molecules (CD4, CD5, CD7).
- Analysis of therapeutic approaches involving the blockade of proinflammatory cytokines (e.g., TNF alpha, IL-1).
- Investigation into the augmentation of anti-inflammatory cytokines (e.g., IL-10) as a treatment strategy.
Main Results:
- Monoclonal antibodies against CD4, CD5, and CD7 did not demonstrate significant efficacy in RA treatment.
- Therapies blocking tumor necrosis factor alpha (TNF alpha) have shown marked success in controlling RA inflammation and reducing acute phase proteins.
- Anti-TNF alpha therapy necessitates repeated administration due to disease relapse, though feasibility is suggested.
Conclusions:
- Targeting specific molecular pathways, like TNF alpha, represents a significant advancement in treating RA and other immuno-inflammatory conditions.
- Anti-TNF alpha therapy has established a viable molecular target and a novel therapeutic avenue for immuno-inflammatory disorders.
- While effective, sustained control of RA with anti-TNF therapy requires ongoing treatment, highlighting the need for further research into long-term management.